Involvement of leukotriene B4 in murine dermatitis models

Biochemical Pharmacology

Volumn 55, Issue 3, 1998, Pages 297-304

  Tsuji, Fumio ^a   Miyake, Yurika ^a   Horiuchi, Masato ^a   Mita, Shiro ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dermatitis; Leukotriene A4 hydrolase inhibitor; Leukotriene B4; Mice; Psoriasis; SA6541

Indexed keywords

(4 DIMETHYLAMINOBENZYL) N (3 MERCAPTO 2 METHYLPROPIONYL)CYSTEINE; 5 HYDROPEROXY 6,8,11,14 ICOSATETRAENOIC ACID; ARACHIDONIC ACID; BESTATIN; HYDROLASE INHIBITOR; INDOMETACIN; LEUKOTRIENE B4; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ARACHIDONIC ACID 5 HYDROPEROXIDE; ARACHIDONIC ACID 5-HYDROPEROXIDE; CYSTEINE; DRUG DERIVATIVE; ENZYME INHIBITOR; EPOXIDE HYDROLASE; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; NONSTEROID ANTIINFLAMMATORY AGENT; SA 6541;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DERMATITIS; ENZYME INHIBITION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM;

ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CYSTEINE; DERMATITIS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; LEUKOTRIENE B4; LEUKOTRIENES; MALE; MICE; MICE, INBRED ICR;

EID: 0031987313     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00464-4     Document Type: Article

References (45)

1. 4 A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes . Nature. 286:1980;264-265.
2. Bray MA, Ford-Hutchinson AW, Shipley ME, Smith MJH. Calcium ionophore A23187 induces release of chemokinetic and aggregating factors from polymorphonuclear leukocytes. Br J Pharmacol. 71:1980;507-512.
3. 4. J Pharm Pharmacol. 33:1981;616-617.
4. 4 towards rabbit neutrophils. J Immunol. 128:1982;811-816.
5. 4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Invest. 74:1984;1552-1555.
6. Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes Formation of a novel dihydroxyeicosatetraenoic acid . J Biol Chem. 254:1979;2643-2650.
7. 4. Proc Natl Acad Sci USA. 79:1982;7866-7870.
8. 4 in response to IgG stimulation. J Clin Invest. 83:1989;1691-1700.
9. Jakobsson PJ, Steinhilber D, Odlander B, Radmark O, Claesson HE, Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc Natl Acad Sci USA. 89:1992;3521-3525.
10. 4 in inflammation. Crit Rev Immunol. 10:1990;1-12.
11. 4 enhances activation, proliferation and differentiation of human B lymphocytes. J Immunol. 143:1989;1996-2000.
12. 4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes. Agents Actions. 34:1991;42-45.
13. 4 transcriptionally activates interleukin-6 expression involving NK-κB and NF-IL6. Eur J Immunol. 22:1992;2705-2711.
14. 4 augments interleukin-2-receptor-beta (IL-2Rβ) expression and IL-2Rβ-mediated cytotoxic response in human peripheral blood lymphocytes. Immunology. 76:1992;258-263.
15. 4 induces interleukin-5 generation from human T lymphocytes. Eur J Immunol. 23:1993;2392-2398.
16. Higgs GA, Salmon JA, Spayne JA. The inflammatory effects of hydroperoxy and hydroxy acid products or arachidonate lipoxygenase in rabbit skin. Br J Pharmacol. 74:1981;429-433.
17. Wedmore CV, Williams JJ. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 289:1981;646-650.
18. 4) in the rabbit. Am J Pathol. 115:1984;233-244.
19. 2 . J Invest Dermatol. 88:1987;120-123.
20. 4 during experimental inflammation. Biochem Pharmacol. 32:1983;1353-1354.
21. Aked DM, Foster SJ. The contribution of eicosanoids to the acute inflammatory reaction induced by arachidonic acid in rabbit skin. Br J Pharmacol. 92:1987;545-552.
22. Aked DM, Foster SJ, Howarth A, McCormick ME, Potts HC. The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation. Br J Pharmacol. 89:1986;431-438.
23. 4 receptor antagonist SC-41930 . Inflammation. 14:1990;727-739.
24. 4 on eosinophil infiltration in response to C5a in guinea-pig skin. Br J Pharmacol. 113:1994;117-120.
25. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 372:1994;179-182.
26. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA. 91:1994;12852-12856.
27. 4) in human skin. J Invest Dermatol. 80:1983;115-119.
28. 4. J Invest Dermatol. 82:1984;202-204.
29. 4 in the human lung Recruitment of neutrophils into alveolar spaces without a change in protein permeability . J Clin Invest. 84:1989;1609-1619.
30. 4. J Dermatol. 18:1991;271-276.
31. 4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis. 42:1983;677-679.
32. 4 in purulent peritoneal exudates demonstrated by GC-MS. Prostaglandins Leukot Med. 23:1986;85-94.
33. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 86:1984;453-460.
34. 4-like material in biologically active amounts from lesional skin of patients with psoriasis. J Invest Dermatol. 83:1984;70-73.
35. 4 detected in the broncho-alveolar lavage fluid of patients with non-cardiogenic pulmonary edema, but not in those with cardiogenic edema. Intensive Care Med. 17:1991;1-6.
36. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway Biochemistry and relations to pathobiology in human diseases . N Engl J Med. 323:1990;645-655.
37. 4 hydrolase in the human lung. J Biol Chem. 262:1987;10200-10205.
38. De Young LM, Kheifets JB, Ballaron SJ, Young JM. Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. Agents Actions. 26:1989;335-341.
39. 4 hydrolase. FEBS Lett. 297:1992;139-142.
40. 4 hydrolase. Biochem Pharmacol. 48:1994;131-137.
41. Harris RR, Carter GW, Bell RL, Moore JL, Brooks DW. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol. 17:1995;147-156.
42. Woollard PM. Stereochemical differences between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. Biochem Biophys Res Commun. 136:1986;169-176.
43. 4 from leukocyte membrane preparations by (12R)- and (12S)-hydroxyeicosatetraenoic acid. Biochim Biophys Acta. 917:1987;406-410.
44. 4 receptor antagonist CP-105696. J Pharmacol Exp Ther. 273:1995;176-184.
45. Ford-Hutchinson AW. 5-Lipoxygenase activation in psoriasis A dead issue? Skin Pharmacol. 6:1993;292-297.